GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eloxx Pharmaceuticals Inc (OTCPK:ELOX) » Definitions » Shares Outstanding (EOP)

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Shares Outstanding (EOP) : 3.07 Mil (As of Sep. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Eloxx Pharmaceuticals Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Eloxx Pharmaceuticals's shares outstanding for the quarter that ended in Sep. 2023 was 3.07 Mil.

Eloxx Pharmaceuticals's quarterly shares outstanding increased from Jun. 2023 (2.49 Mil) to Sep. 2023 (3.07 Mil). It means Eloxx Pharmaceuticals issued new shares from Jun. 2023 to Sep. 2023 .

Eloxx Pharmaceuticals's annual shares outstanding increased from Dec. 2021 (2.17 Mil) to Dec. 2022 (2.17 Mil). It means Eloxx Pharmaceuticals issued new shares from Dec. 2021 to Dec. 2022 .


Eloxx Pharmaceuticals Shares Outstanding (EOP) Historical Data

The historical data trend for Eloxx Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eloxx Pharmaceuticals Shares Outstanding (EOP) Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 1.00 1.00 2.17 2.17

Eloxx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.17 2.17 2.17 2.49 3.07

Competitive Comparison of Eloxx Pharmaceuticals's Shares Outstanding (EOP)

For the Biotechnology subindustry, Eloxx Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eloxx Pharmaceuticals's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's Shares Outstanding (EOP) falls into.



Eloxx Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Eloxx Pharmaceuticals  (OTCPK:ELOX) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Eloxx Pharmaceuticals Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Watertown, MA, USA, 02472
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.
Executives
Sumit Aggarwal director, officer: PRESIDENT AND CEO 480 ARSENAL WAY, WATERTOWN MA 02472
Vijay Modur officer: HEAD OF R&D C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER ST., WALTHAM MA 02451
Lindsay Androski director C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Gadi Veinrib director 12 MIKHA'EL NE'EMAN ST, TEL AVIV-YAFO L3 6958101
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Jasbir Seehra director C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Zafrira Avnur director 210 ALLANDALE ST #1B, CHESTNUT HILL MA 02467
Alan Edmund Walts director 197 8TH STREET, APARTMENT 804, CHARLESTOWN MA 02129
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Pontifax Iv Gp L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax Management 4 G.p. (2015) Ltd. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (israel) Iv, L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (china) Iv L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (cayman) Iv L.p. 10 percent owner 4 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Headlines

From GuruFocus